Robyn Jackson, MBA, CNMT Joins Telix Pharmaceuticals US
January 7, 2020 - Telix Pharmaceuticals is pleased to announce the addition of Robyn Jackson to our US Team!
With over 15 years of hands-on experience in Diagnostic Imaging and Sales, Robyn will be solidifying our presence in the Western US. Robyn has an extensive background in Diagnostic Imaging including Nuclear Medicine, Positron Emission Tomography (P.E.T.) and Radiologic Technology. She began her career in the clinical setting as a Radiologic Technologist specializing in Computed Tomography (CT), Mammography and expanding her training at Loma Linda Medical University in Nuclear Medicine Technology. Robyn holds four radiology board certifications by American Registry of Radiologic Technologist in Radiology, Mammography, Computed Tomography (C.T.) and Nuclear Medicine, as well as Nuclear Medicine Technologist Certification Board (NMTCB).
Robyn worked clinically at various academic centers in and around Los Angeles area hospitals including Cedars Sinai Medical Center, Hoag Memorial Hospital, Good Samaritan Medical Center and UCLA Medical Center before going into commercial sales. Her professional sales career encompasses Bristol Myers Squibb (BMS) where she managed Los Angeles area with Cardiovascular product portfolio. At BMS she managed imaging agents Cardiolite and Definity as well as Plavix antiplatelet therapy, Coumadin Anticoagulant and Hypertension products. In 2009, Robyn received Bristol Myers Pinnacle Award for achieving highest ranking sales goal in district for all four quarters. She also received other honors for driving market share and district collaboration. In 2011, she joined Covidien during the Mallinckrodt acquisition. At Covidien-Mallinckrodt Robyn managed their nuclear medicine product portfolio for ten states on the West Coast managing Hospital accounts, Commercial and Independent Radiopharmacies. While at Mallinckrodt she turned underperforming accounts into high revenue generating accounts. This led Robyn as a twice recipient of Mallinckrodt Pharmaceuticals 2016 and 2015 Account Manager of the Year award for achieving highest ranking quotas for the whole US market in all products. In addition, she received other recognition for consecutively exceeding fiscal year quotas.
In 2018, Robyn joined Medtronic Device managing Coronary products coronary stents, balloons and catheters in Los Angeles area.
Robyn’s education comprises a Master’s in Business Administration with a focus in Supply Chain Management from California State University San Bernardino. Her undergraduate degree is from California State University Dominguez Hills in Radiologic Technology minor in marketing.
Robyn resides in Southern California with her twin daughters. She enjoys hiking, traveling and being amongst her family and friends.
We welcome Robyn to the organization as we continue to grow our team in the US Market.
Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)
Melbourne (Australia) – 25 Feb 2020. Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its...
Telix Pharmaceuticals Releases Annual Report Year Ending 2019
Melbourne (Australia) - 24 Feb 2020. Telix Pharmaceuticals Limited is pleased to provide its Annual Report for the year ending...
European Leadership Changes and Appointment of VP Sales and Marketing, EMEA
Melbourne (Australia) – 21st February 2020. Telix Pharmaceuticals Limited announces that Ms Odile Jaume will be stepping down from her...
Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging
Melbourne (Australia) – 23 January 2020. Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON...
NDA Clinical Briefing Package Submitted to the US FDA
Melbourne (Australia) – 27 Dec 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a complete clinical...
TLX101 for Brain Cancer IPAX-1 Study Update
Melbourne (Australia) – 23 December 2019. Telix Pharmaceuticals has released an update on the progress of its TLX101 product being...
ZIRCON Phase 3 IND Submitted to the US FDA
Melbourne (Australia) – 24 December 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a Phase 3...
University of Melbourne collaboration with Telix receives Cancer Australia research grant
Melbourne (Australia) – 19th December 2019. Telix Pharmaceuticals Limited (ASX: TLX) is pleased to announce that Telix collaborator Professor Frédéric...
Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer
Melbourne (Australia) and Nantes (France) – 16, Dec 2019. Telix Pharmaceuticals Limited and French company ATONCO S.A.S today announce that...
Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference
Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at...